Christopher Van Dyck, MD
1 Church St 8th Floor, New Haven, CT 06510
5.0
(1 reviews)
About the Practice
He was the lead author on the study that established lecanemab as the first disease-modifying treatment for Alzheimer’s disease. Predictive and monitoring value of blood‐based biomarkers for apathy treatment in Alzheimer’s disease.
Category
ADHD
Aging/Elderly
Childhood Trauma
Depression
Gender Identity
Grief
LGBTQ+
Sexual Abuse
Insurance Accepted
EmblemHealth
Reviews & Ratings
5.0
1 total reviews
Contact Provider
View on MapsIs this your practice?
Claim your free profile today
Update your info, respond to reviews, and connect with new clients.
Claim This ProfileRequest Appointment
Christopher Van Dyck, MD